De Lima, Rachel
De Lima, Rachel was paid $93K by Medicaid between Dec 2023 and Aug 2024, across 5 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 75% of everything it billed.
33Billing provider infoDE LIMA, RACHEL
COLUMBUS, OH 43204
COLUMBUS, OH 43204
33aNPI1215596788assigned 06/10/2019
33bProvider typeRegistered Nurse
28Total paid$93K
24GClaims908
24DCodes billed5
24AFirst – last monthDec 2023 – Aug 2024
Compared with peers
Next to other Registered Nurse providers in Ohio
Rank by total paid#11 of 108
Median peer was paid$4K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 66 | $6K | |
| 2024incomplete | 842 | $88K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 75% | 599 | 410 | $70K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 14% | 82 | 82 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.8% | 155 | 143 | $6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 4.0% | 33 | 32 | $4K |
| 82075 | <1% | 39 | 39 | $832.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.